Requirement for MAPK activity was confirmed pharmacologically: the ERK inhibitor SCH772984 abolished BCM-induced phospho-ERK1/2 in B cells and concurrently reversed the increase in IFN-γ+CD8+T cells. Here, MAPK3 is linked to blue cone monochromacy.